Partial
Partially Aligned
Patient Risk:
Low
Summary
Only the indication-related claims for schizophrenia and bipolar depression are supported by the provided FDA label excerpt; all other claims are not supported by the supplied label sections and include several statements outside the prescribing information scope.
Category Scores
Accurate Statements
Lurasidone (Latuda) is used to treat schizophrenia.
Indications and Usage: “Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia.”
Lurasidone (Latuda) is used to treat bipolar depression.
Indications and Usage: “Monotherapy treatment … with major depressive episode associated with bipolar I disorder (bipolar depression)” and “Adjunctive treatment with lithium or valproate … (bipolar depression).”
Unsupported Statements
The first generic lurasidone was approved in the U.S. in 2023.
Not supported by the provided FDA label excerpts.
Several generic versions of lurasidone have received or are anticipated to receive U.S. Food and Drug Administration (FDA) approval.
Not supported by the provided FDA label excerpts.
Teva Pharmaceuticals was among the first to receive FDA approval for a generic version of lurasidone.
Not supported by the provided FDA label excerpts.
Lurasidone has been protected by patents covering its chemical composition and methods of use.
Not supported by the provided FDA label excerpts.
Patents for lurasidone grant market exclusivity to the innovator drug, delaying generic competition.
Not supported by the provided FDA label excerpts.
As lurasidone patents expire or are successfully challenged, generic manufacturers can seek FDA approval.
Not supported by the provided FDA label excerpts.
Generic drugs are required to demonstrate bioequivalence to their brand-name counterparts.
Not supported by the provided FDA label excerpts.
Bioequivalence means generic drugs contain the same active ingredient as the brand-name drug.
Not supported by the provided FDA label excerpts.
Bioequivalence means the generic drug is absorbed into the bloodstream at the same rate and to the same extent as the brand-name drug.
Not supported by the provided FDA label excerpts.
Generic lurasidone will have the same therapeutic effect as Latuda.
Not supported by the provided FDA label excerpts.
Differences between generic lurasidone and Latuda may exist in inactive ingredients.
Not supported by the provided FDA label excerpts.
Differences in inactive ingredients can affect formulation but not efficacy or safety for most patients.
Not supported by the provided FDA label excerpts.
Generic lurasidone is considered as safe and effective as brand-name Latuda for most patients.
Not supported by the provided FDA label excerpts.
Rare adverse reactions related to inactive ingredients can occur in individuals with specific sensitivities to those ingredients.
Not supported by the provided FDA label excerpts.
Prescribers and patients should report unexpected side effects to the FDA.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
Any label-based information relevant to dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, or specific populations was not addressed in the provided claims set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned claims are indication statements. The non-supported claims are primarily about generic approvals/patents/bioequivalence and reporting language; no dosing, contraindications, boxed warnings, or specific safety instructions were claimed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the supplied FDA label sections and include generic/patent/bioequivalence assertions that are outside the provided prescribing information evidence.
Suggested Improvement
Limit claims to the label-supported Indications section (schizophrenia; bipolar depression indications) and remove or qualify all generic/patent/bioequivalence/efficacy-equivalence and reporting-to-FDA statements unless supported by the provided label text.